This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Worldwide, over 800 million people are affected by kidneydisease, yet its pathogenesis remains elusive, hindering the development of novel therapeutics. Lipid accumulation and the expression of genes related to DNL were elevated in the kidneys of patients with fibrosis.
Ten percent of the population worldwide suffers from chronic kidneydisease (CKD), but the mechanisms driving CKD pathology are incompletely understood. Identify acyl-CoA synthetase short-chain family 2 (ACSS2) as a disease risk gene and demonstrate a role for ACSS2 in de novo lipogenesis (DNL).
We aimed to determine the clinical characteristics which were associated with optimisation of HF pharmacological intervention in the clinic, conducting multivariate regression analysis. Frailty, chronic kidneydisease and ischaemic heart disease increased significantly versus the first period (p<0.001).
While it is known to increase serotonin levels in the brain and gastrointestinal tract, its pharmacology remains largely unexplored. However, the role of 5-HTP in vascular disease is not well understood. to 2.31); chronic kidneydisease 1.07 (0.33 95% CI = 2.6 to 40686.5). to 1.77); dyslipidemia 0.91 (0.5
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally. CVD and kidneydisease are closely related, with kidney injury increasing CVD mortality. CVD and kidneydisease are closely related, with kidney injury increasing CVD mortality.
Cox regression analysis revealed chronic kidneydisease (CKD) (hazard ratio (HR) 2.05, 95% confidence interval (CI) [1.04,4.05] (p= 0.038)] and warfarin use [(HR 4.94, 95% CI [1.11,22.09] (p= 0.037)] to be independent predictors of mortality at 12 months.
After discontinuing these medications, patients were randomly assigned to take one of three once-daily medications (indapamide, amlodipine or olmesartan) that are commonly used in clinical practice, representing different pharmacologic mechanisms for reducing blood pressure.
Bakris’s distinguished career in medicine spanned over four decades, marked by significant contributions to the fields of diabetic kidneydisease, hypertension, and nephropathy progression. His work was particularly influential in understanding racial disparities in disease progression and developing targeted interventions.
Among those ages 65 and older, nearly 50% who underwent limb amputation died within one year after surgery, according to the 2024 Heart Disease and Stroke Statistics: A Report of U.S. Pharmacological and behavioral-based strategies often increase the smoking cessation rate in people with PAD, however, these strategies are underused.
colchicine which poses the greatest risk among patients 65 or older who may have declining liver or kidney function.38 Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review. For most individuals, these gastrointestinal effects markedly attenuate with longer-term therapy.34 μ/L on 0.6 2015.06.013 31.
Based on these results, updated diabetes guidelines recommend that in T2D patients with atherosclerotic cardiovascular disease, we should use GLP-1 RAs, and in T2D patients with heart failure or chronic kidneydisease, we should use an SGLT-2 inhibitor after first-line therapy with lifestyle and metformin [25]. Diabetes Care 42.Supplement
He also had a history of chronic kidneydisease, stage III. Angio had shown some acute disease in the saphenous vein graft to the posterior descending artery off of the RCA. Crit Care Med 1991; 19:694) Concentrated Potassium Chloride Infusions in Critically Ill Patients with Hypokalemia The Journal of Clinical Pharmacology.
The trafficking dynamics of uromodulin (UMOD), the most abundant protein in human urine, play a critical role in the pathogenesis of kidneydisease. Monoallelic mutations in the UMOD gene cause autosomal dominant tubulointerstitial kidneydisease (ADTKD-UMOD), an incurable genetic disorder that leads to kidney failure.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content